Tempus AI, Inc. (TEM)
NASDAQ: TEM · Real-Time Price · USD
54.89
-1.70 (-3.00%)
At close: Aug 1, 2025, 4:00 PM
54.75
-0.14 (-0.26%)
After-hours: Aug 1, 2025, 7:59 PM EDT
Aspen Technology Revenue
Tempus AI had revenue of $255.74M in the quarter ending March 31, 2025, with 75.38% growth. This brings the company's revenue in the last twelve months to $803.32M, up 42.93% year-over-year. In the year 2024, Tempus AI had annual revenue of $693.40M with 30.38% growth.
Revenue (ttm)
$803.32M
Revenue Growth
+42.93%
P/S Ratio
10.02
Revenue / Employee
$334,715
Employees
2,400
Market Cap
9.51B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 693.40M | 161.58M | 30.38% |
Dec 31, 2023 | 531.82M | 211.15M | 65.85% |
Dec 31, 2022 | 320.67M | 62.82M | 24.36% |
Dec 31, 2021 | 257.85M | 69.85M | 37.15% |
Dec 31, 2020 | 188.00M | 125.95M | 202.95% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
TEM News
- 1 day ago - Tempus AI: Next Leg Up - Seeking Alpha
- 3 days ago - Tempus AI: Data‑Driven Margin Lift, But Cash Burn Extends My Hold Stance - Seeking Alpha
- 3 days ago - Tempus AI: Sustaining Growth Momentum With Acquisitions & Partnerships - Seeking Alpha
- 10 days ago - Tempus to Report Second Quarter 2025 Financial Results on August 8 - Business Wire
- 16 days ago - Tempus Receives U.S. FDA 510(k) Clearance for Tempus ECG-Low EF Software - Business Wire
- 22 days ago - Apple Acquisition Buzz: Its $60 Billion War Chest Is Enough To Buy Datadog And Tempus - Benzinga
- 23 days ago - Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients - Business Wire
- 24 days ago - Tempus Expands AI-Enabled Care Pathway Intelligence Platform into Breast Cancer - Business Wire